|会社名||Cutera Inc （キュテラ）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Electromedical_Electrotherapeutic Apparatus|
|業種||先端医療機器_テクノロジ― 医療関連（Health Care）|
|概要||事業概要 キュテラ(Cutera Inc.)は医療機器会社である。同社は世界中の開業医に提供するレーザーおよびその他のエネルギーベース美容システムの設計、開発、製造、マーケティング、サービスを行う。同社は医師や他の開業医が美容整形の実行を可能にするenlighten、excel HR、truSculpt、excel Vとxeoなどを含む製品プラットフォームを提供する。同社の各レーザーと光ベースのプラットフォームは１つまたは複数のハンドピース、及び１つのグラフィック?ユーザー?インターフェース、１つのレーザーや光ベースのモジュール、制御システムソフトウェアおよび高電圧電子機器を内蔵した１つのコンソールで構成される。同社もCV、ExcelとVantageを含むCoolGlide、Titan S、ProWave 770、OPS 600、LP560、AcuTip 500、Titan V/XLとLimeLightを含むSolera、及び日本市場向けの第三者ソースシステムmyQを提供する。 キュテラは、米国の医療機器メ―カ―。レ―ザ―光治療器をはじめとする医療機器の設計、開発、製造、販売、修理などを行う。主な製品は、美容医療治療器｢ゼオ｣、爪水虫治療器｢ジェネシス・プラス｣、部分痩身器｢トゥル―・スカルプ｣など。本社は、カリフォルニア州ブリスベン。 Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients.|
|本社所在地||3240 Bayshore Blvd. Brisbane CA 94005 USA|
|代表者氏名||J. Daniel Plants J.ダニエル・プラント|
|代表者役職名||Independent Chairman of the Board|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Cutera Inc. revenues increased 17% to $76.7M. Net loss totaled $3.6M vs. income of $925K. Revenues reflect United States segment increase of 21% to $49.3M. Net loss reflects Selling General_Admin increase of 21% to $27.5M (expense) General_admin exp increase of 49% to $8.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $0.07 to -$0.26.|
Cutera gets FDA warning letter over a website promoting a device for vaginal procedures 2022/12/01 22:16:03 Seeking Alpha
Cutera (CUTR) on Thursday said it had recently been issued a warning letter from the U.S. FDA regarding marketing material over a device that the company stopped promoting in 2019
Cutera, Inc. Provides Response to FDA Inquiry 2022/12/01 21:30:00 Wallstreet:Online
Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today disclosed that it has provided a response to a recent FDA inquiry. In 2019, Cutera undertook remediation to remove all marketing materials related to gynecological indications, including vaginal rejuvenation, for a device designed and manufactured by a third party.
Cutera Stock: AviClear Key Differentiator, Reaffirm Buy (NASDAQ:CUTR) 2022/12/01 10:54:58 Seeking Alpha
AviClear revenue growth was the key standout for Cutera, with >160 devices now in the installed base. Find out why we rate CUTR stock a buy.
Cutera, Inc. to Participate in a Fireside Chat at the 34th Annual Piper Sandler Healthcare Conference 2022/11/21 22:00:00 Wallstreet:Online
Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and Greg Barker, Vice President, Corporate FP&A, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference at 2:00 pm ET on Wednesday, November 30, 2022, at the Lotte New York Palace
Cutera, Inc. to Participate in a Fireside Chat at the Stephens Annual Investment Conference 2022/11/10 22:10:00 Wallstreet:Online
Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and Greg Barker, Vice President, Corporate FP&A, will participate in a fireside chat at the Stephens Annual Investment Conference at 4:00 pm CT on Wednesday, November 16, 2022, at the Grand Hyatt Hotel, Nashville, TN.
Cutera surges 12% as FY22 revenue outlook maintained despite forex impact 2022/11/04 13:36:34 Seeking Alpha
Cutera (CUTR) stock rose ~21% premarket on Friday after Q3 revenue beat estimates and the company reaffirmed its FY22 outlook despite foreign exchange headwinds.GAAP net loss widened…
Cutera Soars on Positive Demand Momentum 2022/11/04 11:58:29 TipRanks
Shares of aesthetic and dermatology solutions provider Cutera (NASDAQ:CUTR) have skyrocketed today on the back of its third-quarter showing. Revenue rose 9.4% year-over-year to $62.8 million, in line with estimates. Net loss per share at $0.62 though, came in wider than estimates by $0.24. Nonetheless, the company is seeing capital equipment and consumable product demand and witnessed more than 100 new placements of AviClear devices during the quarter. Looking ahead, for 2022, Cutera now expects to end the year at the upper end of its top-line guidance of $255 million and $260 million. In constant currency terms, this indicates a growth between 18% and 20%.
FNKO, TEAM and CMBM are among after hours 2022/11/03 22:16:50 Seeking Alpha
Gainers: BioAtla (BCAB) +43%. Cutera (CUTR) +23% TransMedics (TMDX) +20%.
Cutera Announces Third Quarter 2022 Financial Results 2022/11/03 20:01:00 Business Wire
Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results f
Cutera, Inc. to Announce Third Quarter Results on November 3, 2022 2022/10/20 21:53:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the third quarter of 2022 after the market close on Thursday, November 3, 2022. The Company’s management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m. ET) that same day. To join the conference call, dial 1-800-319-4610 (domestic) or +1-
Cutera’s AviClear Clinical Data Presented at the Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2022/05/02 12:00:00 Wallstreet:Online
CUTERA, INC. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of dermatology solutions, today announced that clinical data related to AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne; was presented during the annual meeting of the American Society for Laser Medicine and Surgery (ASLMS) which took place from April 27-30
Cutera, Inc. to Announce First Quarter Results on May 10, 2022 2022/04/28 02:12:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter of 2022 after the market close on Tuesday, May 10, 2022. The Company’s management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m. ET) that same day. To join the conference call, dial 1-800-381-7839 (domestic) or +1-416-9
Cutera, Synchrony team up for financing options for patients using acne device AviClear 2022/04/20 17:45:28 Seeking Alpha
Cutera (CUTR) and Synchrony (SYF) entered an exclusive partnership to expand patient financing options to dermatology practices in the U.S.The companies said that dermatologists…
NICE Enlighten XO Awarded 2022 CUSTOMER Magazine Product of the Year Award 2022/04/11 10:30:00 Kwhen Finance
Medical Aesthetics Market anticipated to grow at a CAGR of 9.5 % by 2030 | MDC Research 2022/04/05 11:32:18 Benzinga
Pune, April 05, 2022 (GLOBE NEWSWIRE) -- The global Medical Aesthetics market is driven by awareness about aesthetic and acceptance of medical aesthetic procedure, rise in minimally invasive procedure for surgeries, rise in medical tourism for aesthetics and advancement & introduction of new cost effective products in the market. However, high cost related to medical aesthetics products and surgeries and complications & risk associated with various medical aesthetic procedures is likely to restrain the market to certain extent. Medical Aesthetics Market by Regions The global Medical Aesthetics market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the market of medical aesthetics, followed by Europe and Asia Pacific. North America will continue to dominate the global medical aesthetics market in the forecast period owing to factors such as increasing focus of population on its appearance and acceptance of aesthetic surgeries to improve overall physical appearance.